You are here

P&T News

January 9

Researchers collaborated to study the effect of advances in screening and treatment
Replacing daily pills with a weekly regimen could help patients adhere to therapy
The drug also has fast-track, orphan drug, and rare pediatric disease status

January 8

Medication used as monotherapy for high-risk cases
Getting the shot every year was about twice as effective
Drug previously limited to those with solid tumors

January 4

So-called “association plans” would be cheaper but cover less
The industry expected the gene therapy for a rare form of blindness to cost $1 million
Atcell is derived from adipose and meant for autologous use

January 2

But average returns on research and development have fallen
The mechanism of action is not fully understood, but additional trials are indicated

December 28

Valsartan was first FDA-approved in 2001 as Diovan tablets
Brand-name Reyataz (Bristol-Myers Squibb) generated annual sales of more than $400 million in 2017
The minimally invasive technology is a synthetic, resorbable bone-graft substitute

December 26

The noninvasive technology is used in conjunction with breast-conserving treatment
Agent increases BP in adults with septic or other distributive shock
An SGLT2 inhibitor and two fixed-dose combinations will be available in January and February 2018

December 21

Recurrence-free survival superior to Yervoy in trial
FDA announces that four studies showed no increased risk of death